Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 7.68 USD -7.02% Market Closed
Market Cap: 350.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+459%
Revenue
Forecast
+101%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

CAPR Price Targets Summary
Capricor Therapeutics Inc

Wall Street analysts forecast CAPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CAPR is 42.97 USD with a low forecast of 25.25 USD and a high forecast of 80.85 USD.

CAPR Lowest Forecast
Wall Street Target
25.25 USD
229% Upside
CAPR Average Forecast
Wall Street Target
42.97 USD
459% Upside
CAPR Highest Forecast
Wall Street Target
80.85 USD
953% Upside
Lowest
Price Target
25.25 USD
229% Upside
Average
Price Target
42.97 USD
459% Upside
Highest
Price Target
80.85 USD
953% Upside
Capricor Therapeutics Inc Competitors:
Price Targets
DVAX
Dynavax Technologies Corp
149% Upside
E
206650
EuBiologics Co Ltd
28% Upside
C
2487
Cutia Therapeutics
12% Upside
PYC
PYC Therapeutics Ltd
190% Upside
DVAX
Dynavax Technologies Corp
149% Upside
E
206650
EuBiologics Co Ltd
28% Upside
C
2487
Cutia Therapeutics
12% Upside
PYC
PYC Therapeutics Ltd
190% Upside
S
SVE
Synthaverse SA
34% Upside
PHARM
Pharming Group NV
592% Upside
ZNTL
Zentalis Pharmaceuticals Inc
356% Upside
SPRY
ARS Pharmaceuticals Inc
95% Upside

Revenue
Forecast

Revenue Estimate
Capricor Therapeutics Inc

For the last 8 years the compound annual growth rate for Capricor Therapeutics Inc's revenue is 24%. The projected CAGR for the next 3 years is 101%.

24%
Past Growth
101%
Estimated Growth
Estimates Accuracy
18%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Capricor Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Capricor Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss
What are analyst estimates?

See Also

Summary
CAPR intrinsic value, competitors valuation, and company profile.
DCF Valuation
CAPR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CAPR stock valuation using valuation multiples.
Wall Street Estimates
CAPR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CAPR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CAPR's stock price target?
Price Target
42.97 USD

According to Wall Street analysts, the average 1-year price target for CAPR is 42.97 USD with a low forecast of 25.25 USD and a high forecast of 80.85 USD.

What is Capricor Therapeutics Inc's Revenue forecast?
Projected CAGR
101%

For the last 8 years the compound annual growth rate for Capricor Therapeutics Inc's revenue is 24%. The projected CAGR for the next 3 years is 101%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.